OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001
OPKO Health said OPKO Biologics dosed the first participant in a Phase 1/2a trial of OPK-8801001 for acromegaly.
OPKO Health said OPKO Biologics dosed the first participant in a Phase 1/2a trial of OPK-8801001 for acromegaly.